Posted by Michael Wonder on 28 Nov 2025
PHARMAC proposes funding for rare disorder treatment
26 November 2025 - PHARMAC is proposing to fund nitisinone for people with the rare disorders - tyrosinaemia type 1 and alkaptonuria.
Nitisinone is currently funded through Pharmac’s Named Patient Pharmaceutical Assessment (NPPA) pathway. Under this proposal, it would be listed on the Pharmaceutical Schedule, making it easier for clinicians to prescribe and for people to access treatment.
